{
  "paper_metadata": {
    "pmid": "34729535",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted information on the TTR gene variant V122I, including penetrance data from affected and unaffected carriers."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.349G>A",
      "protein_notation": "p.Val122Ile",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 3,
        "demographics": "62-year-old Black American male, 68-year-old Black American male, 64-year-old Black American female",
        "phenotype": "hATTR cardiac amyloidosis with varying severity"
      },
      "penetrance_data": {
        "total_carriers_observed": 3,
        "affected_count": 2,
        "unaffected_count": 1,
        "uncertain_count": null,
        "penetrance_percentage": 66.67,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case 1",
          "age_at_evaluation": 62,
          "age_at_onset": 61,
          "age_at_diagnosis": 62,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "heart failure, severe diastolic dysfunction, advanced cardiac amyloidosis",
          "evidence_sentence": "Mr. C initiated disease-modifying therapy with tafamidis; however, his heart failure continued to advance, and he underwent isolated heart transplantation 2 years later."
        },
        {
          "individual_id": "Case 2",
          "age_at_evaluation": 68,
          "age_at_onset": null,
          "age_at_diagnosis": 68,
          "sex": "male",
          "affected_status": "unaffected",
          "phenotype_details": "occasional mild shortness of breath, normal cardiac function",
          "evidence_sentence": "Mr. L could not afford therapy with tafamidis and enrolled in a clinical trial for a novel TTR stabilizer."
        },
        {
          "individual_id": "Case 3",
          "age_at_evaluation": 64,
          "age_at_onset": null,
          "age_at_diagnosis": 64,
          "sex": "female",
          "affected_status": "unaffected",
          "phenotype_details": "mild shortness of breath with exertion, normal cardiac function",
          "evidence_sentence": "Due to the lack of objective evidence of TTR cardiac amyloidosis, Ms. T was not started on prophylactic treatment."
        }
      ],
      "functional_data": {
        "summary": "The V122I mutation is associated with hereditary ATTR, leading to variable clinical presentations.",
        "assays": []
      },
      "segregation_data": "Yes, the variant segregates with disease in the family.",
      "population_frequency": "The V122I gene mutation is highly prevalent among Black Americans.",
      "evidence_level": "Strong evidence based on clinical presentation and family segregation.",
      "source_location": "Main Text, Case 1, Case 2, Case 3",
      "additional_notes": "The penetrance of the V122I mutation varies significantly between individuals, particularly between sexes.",
      "key_quotes": [
        "The V122I gene mutation is highly prevalent among Black Americans, and the phenotypic penetrance is variable.",
        "Hereditary ATTR is an autosomal dominant condition where homozygous patients may present with earlier onset and more severe symptoms than their heterozygous counterparts."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data was extracted from the main text."
  }
}